JP2024513485A5 - - Google Patents
Info
- Publication number
- JP2024513485A5 JP2024513485A5 JP2023561706A JP2023561706A JP2024513485A5 JP 2024513485 A5 JP2024513485 A5 JP 2024513485A5 JP 2023561706 A JP2023561706 A JP 2023561706A JP 2023561706 A JP2023561706 A JP 2023561706A JP 2024513485 A5 JP2024513485 A5 JP 2024513485A5
- Authority
- JP
- Japan
- Prior art keywords
- cellular immunotherapy
- immunotherapy agent
- molecule
- target antigen
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021901030A AU2021901030A0 (en) | 2021-04-08 | Methods for controlling immune cell activity | |
| AU2021901030 | 2021-04-08 | ||
| PCT/AU2022/050311 WO2022213154A1 (en) | 2021-04-08 | 2022-04-08 | Methods for controlling immune cell activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513485A JP2024513485A (ja) | 2024-03-25 |
| JP2024513485A5 true JP2024513485A5 (enExample) | 2025-04-11 |
Family
ID=83544929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561706A Pending JP2024513485A (ja) | 2021-04-08 | 2022-04-08 | 免疫細胞活性を制御する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250282844A1 (enExample) |
| EP (1) | EP4319793A4 (enExample) |
| JP (1) | JP2024513485A (enExample) |
| CN (1) | CN117157092A (enExample) |
| AU (1) | AU2022253547A1 (enExample) |
| BR (1) | BR112023020659A2 (enExample) |
| CA (1) | CA3213042A1 (enExample) |
| MX (1) | MX2023011807A (enExample) |
| WO (1) | WO2022213154A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026507807A (ja) * | 2023-03-08 | 2026-03-06 | バイオセプター （オースト） プロプライエタリー・リミテッド | 機能不全ｐ２ｘ７受容体に結合するためのキメラ抗原受容体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101555283B (zh) * | 2001-01-17 | 2012-03-21 | 生物权威国际有限公司 | 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途 |
| WO2003020762A1 (en) * | 2001-09-03 | 2003-03-13 | Intreat Pty Limited | Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions |
| AU2009266430B2 (en) * | 2008-07-04 | 2014-08-14 | Biosceptre International Limited | Anti- P2X7 peptides and epitopes |
| ES2699753T3 (es) * | 2014-01-29 | 2019-02-12 | Biontech Ag | Mimótopos peptídicos de claudina 18.2 y sus usos |
| EP3484455A2 (en) * | 2016-07-15 | 2019-05-22 | Novartis AG | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| US10986601B2 (en) * | 2017-07-26 | 2021-04-20 | Panoramic Power Ltd. | System and method for timing synchronization of a self-powered power sensor |
| CA3211323A1 (en) * | 2021-03-11 | 2022-09-15 | Patrick Schlegel | Novel cell therapy system |
-
2022
- 2022-04-08 BR BR112023020659A patent/BR112023020659A2/pt unknown
- 2022-04-08 AU AU2022253547A patent/AU2022253547A1/en active Pending
- 2022-04-08 JP JP2023561706A patent/JP2024513485A/ja active Pending
- 2022-04-08 EP EP22783698.8A patent/EP4319793A4/en active Pending
- 2022-04-08 CA CA3213042A patent/CA3213042A1/en active Pending
- 2022-04-08 MX MX2023011807A patent/MX2023011807A/es unknown
- 2022-04-08 CN CN202280026923.7A patent/CN117157092A/zh active Pending
- 2022-04-08 WO PCT/AU2022/050311 patent/WO2022213154A1/en not_active Ceased
- 2022-04-08 US US18/285,621 patent/US20250282844A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102879284B1 (ko) | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 | |
| CN112074279B (zh) | 人源化bcma抗体和bcma-car-t细胞 | |
| TWI883026B (zh) | 抗ｄｌｌ３嵌合抗原受體及其用途 | |
| EP3472205B1 (en) | Chimeric antigen receptor | |
| US12059436B2 (en) | BCMA-CAR-T cells | |
| JP6722189B2 (ja) | 単量体Ｆｃドメイン | |
| JP7854121B2 (ja) | 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法 | |
| JP2019525771A5 (enExample) | ||
| EP4400516A1 (en) | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 | |
| CN114763385B (zh) | 靶向ror1的抗体及其用途 | |
| CN112028996A (zh) | 靶向bcma的单域抗体及其用途 | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| CN108610420A (zh) | 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞 | |
| CA3016287A1 (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
| CN109053899B (zh) | 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体 | |
| US20190177398A1 (en) | Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain | |
| US12103970B2 (en) | CAR-T cells with humanized CD19 ScFv | |
| JP2024532482A5 (enExample) | ||
| JP2024510739A5 (enExample) | ||
| JP2022548112A5 (enExample) | ||
| TW201920272A (zh) | 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用 | |
| JP2024534783A5 (enExample) | ||
| CN113474012A (zh) | Epcam抗体和epcam-car-t细胞 | |
| WO2020112529A1 (en) | Car-t cells having humanized cd19 scfv with mutation in cdr 1 region | |
| CN113271965B (zh) | Cd37抗体和cd37-car-t细胞 |